SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced that the company will participate in the investment focused LSX Nordic Congress on May 19-20, 2026 in Copenhagen. The event provides an excellent platform to engage investors and pharmaceutical partners in supporting SynAct’s development strategy.
SynAct Pharma will participate in meetings throughout the congress represented by Jeppe Øvlesen, CEO; Mads Bjerregaard, CBO; and Ann Kristin Led, CFO. Jeppe Øvlesen, CEO, will present the company at the Biotech Showcase stage on May 19 at 13:15-13:30 and Mads Bjerregaard will join a panel of speakers on “Nordic Deal-Making in 2026: Driving Strategic Partnerships and Growth” on May 19 at 16:10-17:00.
“With topline data from our Phase 2b ADVANCE study approaching we are at a pivotal point in the development of resomelagon and the demonstration of its application in newly diagnosed patients with rheumatoid arthritis. We are actively engaging with strategic partners and investors to support our development strategy to have pro-resolution therapies like resomelagon addressing unmet need for millions of patients with autoimmune and acute inflammatory diseases” says Jeppe Øvlesen, CEO.
The LSX Nordic Congress is the leading life sciences partnering and investment conference in the Nordic region, bringing together biotech, medtech, and health-tech innovators with global investors and strategic partners.